$ALMR News

Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Alamar: The Consumables Flywheel Is Just Getting Started

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences: Promising But Expensive Proteomics Growth

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32

Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum

JP Morgan Maintains Overweight on Alamar Biosciences, Raises Price Target to $35

Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ...

Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales

Alamar Biosciences Q2 Earnings Call Highlights

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

Alamar Biosciences Sees FY2026 Sales $116.000M-$120.000M vs $113.259M Est

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome